

DAFTAR PUSTAKA

- Abal, M., Andreu, J., dan Barasoain, I., 2003. Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action. *Current Cancer Drug Targets*, **3**: 193–203.
- Allison, K.H., Brogi, E., Ellis, I., Fox, S.B., Lakhani, S., Lax, S., dkk. (Editor), 2019. *Breast Tumours*, 5th ed. ed, World health organization classification of tumours. OMS, Geneva.
- Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., dkk. (Editor), 2017. *AJCC Cancer Staging Manual*. Springer International Publishing, Cham.
- Angeli, D., Salvi, S., dan Tedaldi, G., 2020. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? *International Journal of Molecular Sciences*, **21**: 1128.
- Bensalah, K., Montorsi, F., dan Shariat, S.F., 2007. Challenges of Cancer Biomarker Profiling. *European Urology*, **52**: 1601–1609.
- Bignon, L., Fricker, J.-P., Nogues, C., Mouret-Fourme, E., Stoppa-Lyonnet, D., Caron, O., dkk., 2018. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. *The Breast Journal*, **24**: 269–277.
- Blum, J.L., Flynn, P.J., Yothers, G., Asmar, L., Geyer, C.E., Jacobs, S.A., dkk., 2017. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **35**: 2647–2655.
- Børresen-Dale, A.-L., 2003. TP53 and breast cancer. *Human Mutation*, **21**: 292–300.
- Brewer, H.R., Jones, M.E., Schoemaker, M.J., Ashworth, A., dan Swerdlow, A.J., 2017. Family history and risk of breast cancer: an analysis accounting for family structure. *Breast Cancer Research and Treatment*, **165**: 193–200.
- Bunnell, B.A., Martin, E.C., Matossian, M.D., Brock, C.K., Nguyen, K., Collins-Burow, B., dkk., 2022. The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer. *Cancer Metastasis Reviews*, **41**: 549–573.
- Caparica, R., Bruzzone, M., Poggio, F., Ceppi, M., De Azambuja, E., dan Lambertini, M., 2019. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. *Breast Cancer Research and Treatment*, **174**: 27–37.
- Cardinale, D., Iacopo, F., dan Cipolla, C.M., 2020. Cardiotoxicity of Anthracyclines. *Frontiers in Cardiovascular Medicine*, **7**: 26.
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I.T., dkk., 2019. Early breast cancer: ESMO Clinical Practice Guidelines for

- diagnosis, treatment and follow-up. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **30**: 1674.
- Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., dkk., 2018. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **29**: 1634–1657.
- Chavez-MacGregor, M., Litton, J., Chen, H., Giordano, S.H., Hudis, C.A., Wolff, A.C., dkk., 2010. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity. *Cancer*, **116**: 4168–4177.
- Chen, H.H.W. dan Kuo, M.T., 2017. Improving radiotherapy in cancer treatment: Promises and challenges. *Oncotarget*, **8**: 62742–62758.
- Cho, S.Y., Park, S.Y., Bae, Y.K., Kim, J.Y., Kim, E.K., Kim, W.G., dkk., 2021. Standardized pathology report for breast cancer. *Journal of Pathology and Translational Medicine*, **55**: 1–15.
- Choi, M.R., Solid, C.A., Chia, V.M., Blaes, A.H., Page, J.H., Barron, R., dkk., 2014. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **22**: 1619–1628.
- Chu, E. dan DeVita, V.T., 2022. *Physicians' Cancer Chemotherapy Drug Manual 2021*.
- Clarke, S.J. dan Rivory, L.P., 1999. Clinical pharmacokinetics of docetaxel. *Clinical Pharmacokinetics*, **36**: 99–114.
- Costa, R., Hansen, N., dan Gradishar, W.J., 2018. Locally Advanced Breast Cancer, dalam: *The Breast*. Elsevier, hal. 819-831.e6.
- Cserni, G., 2020. Histological type and typing of breast carcinomas and the WHO classification changes over time. *Pathologica*, **112**: 25–41.
- Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., dkk., 2016. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA: a cancer journal for clinicians*, **66**: 309–325.
- Dandamudi, A., Tommie, J., Nommsen-Rivers, L., dan Couch, S., 2018. Dietary Patterns and Breast Cancer Risk: A Systematic Review. *Anticancer Research*, **38**: 3209–3222.
- Delgado, A. dan Guddati, A.K., 2021. Clinical endpoints in oncology - a primer. *American Journal of Cancer Research*, **11**: 1121–1131.
- Dian P, D., Widayati, K., dan Hardianti, M.S., 2021. 'pengaruh Indeks Massa Tubuh Awal Terhadap Kekambuhan Pasien Kanker Payudara Pasca Menopause Subtipe Hr Positif Her2 Negatif Di Rsup Dr. Sardjito (Kajian Pengaruh Terapi Aromatase Inhibitor Steroid versus Nonsteroid)', . ILMU PENYAKIT DALAM Universitas Gadjah Mada.
- Díaz, J.F. dan Andreu, J.M., 1993. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. *Biochemistry*, **32**: 2747–2755.

- Driscoll, J.J. dan Rixe, O., 2009. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. *Cancer Journal (Sudbury, Mass.)*, **15**: 401–405.
- Erol, A., Ho, A.M.-C., Winham, S.J., dan Karpyak, V.M., 2019. Sex hormones in alcohol consumption: a systematic review of evidence: Sex hormones in alcoholism. *Addiction Biology*, **24**: 157–169.
- ESHRE Capri Workshop Group, 2004. Hormones and breast cancer. *Human Reproduction Update*, **10**: 281–293.
- Farr, A., Stolz, M., Baumann, L., Bago-Horvath, Z., Oppolzer, E., Pfeiler, G., dkk., 2017. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. *Breast (Edinburgh, Scotland)*, **33**: 153–158.
- Fentiman, I.S. dan D'Arrigo, C., 2004. Pathogenesis of breast carcinoma. *International Journal of Clinical Practice*, **58**: 35–40.
- Fiolet, T., Srouf, B., Sellem, L., Kesse-Guyot, E., Allès, B., Méjean, C., dkk., 2018. Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort. *BMJ*, k322.
- Fleiss, J.L., Levin, B., dan Paik, M.C., 2003. *Statistical Methods for Rates and Proportions*, 3rd ed. ed, Wiley series in probability and statistics. J. Wiley, Hoboken, N.J.
- Foretová, L., Navrátilová, M., Svoboda, M., Vašíčková, P., Sťahlová Hrabincová, E., Házová, J., dkk., 2019. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer. *Klinická Onkologie*, **32**: .
- Fujii, T., Le Du, F., Xiao, L., Kogawa, T., Barcenas, C.H., Alvarez, R.H., dkk., 2015. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. *JAMA oncology*, **1**: 1311–1318.
- Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., dkk., 2020. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? *Genes*, **11**: 719.
- Gadisa, D.A., Assefa, M., Tefera, G.M., dan Yimer, G., 2020. Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. *Journal of Oncology*, **2020**: 2636514.
- Gajdos, C., Tartter, P.I., Bleiweiss, I.J., Bodian, C., dan Brower, S.T., 2000. Stage 0 to stage III breast cancer in young women1. *Journal of the American College of Surgeons*, **190**: 523–529.
- Gheri, D., Willson, M.L., Chan, M.M.K., Simes, J., Donoghue, E., dan Wilcken, N., 2015. Taxane-containing regimens for metastatic breast cancer. *Cochrane Database of Systematic Reviews*, .
- Giuliano, A.E., Connolly, J.L., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., dkk., 2017. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual: Updates to the

- AJCC Breast TNM Staging System: The 8th Edition. *CA: A Cancer Journal for Clinicians*, **67**: 290–303.
- Gondhowiardjo, S., Purwanto, H., Panigoro, S., Giselvania, A., Widodo, N.H., Nasution, W.N., dkk. (Editor), 2019. *PNPK kanker payudara*. Kementerian Kesehatan RI, Indonesia.
- Gradishar, W.J., Moran, M.S., Abraham, J., Aft, R., Agnese, D., Allison, K.H., dkk., 2021. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. *Journal of the National Comprehensive Cancer Network: JNCCN*, **19**: 484–493.
- Guadagni, F., Cutaia, S., Madonia, G., Gristina, V., Incorvaia, L., Corsini, L.R., dkk., 2021. Biomarkers, dalam: Russo, A., Peeters, M., Incorvaia, L., dan Rolfo, C. (Editor), *Practical Medical Oncology Textbook, UNIPA Springer Series*. Springer International Publishing, Cham, hal. 43–64.
- Gyöngyösi, M., Lukovic, D., Zlabinger, K., Spannbauer, A., Gugerell, A., Pavo, N., dkk., 2020. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. *Cardiovascular Research*, **116**: 970–982.
- Haldar, S., Basu, A., dan Croce, C.M., 1997. Bcl2 is the guardian of microtubule integrity. *Cancer Research*, **57**: 229–233.
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., dkk., 2019. Breast cancer. *Nature Reviews Disease Primers*, **5**: 66.
- Heitzer, E., Lax, S., Lafer, I., Müller, S.M., Pristauz, G., Ulz, P., dkk., 2013. Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma. *BMC Medical Genetics*, **14**: 129.
- Hoffmann, M., Bergner, R., Stützle, M., Uppenkamp, M.J., dan Foerster, R., 2010. Pharmacokinetics of Doxorubicin In Normal Weight and Obese Lymphoma Patients. *Blood*, **116**: 4935–4935.
- Hoskins, L.M., Roy, K., Peters, J.A., Loud, J.T., dan Greene, M.H., 2008. Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support. *Families, Systems, & Health*, **26**: 296–316.
- Hu, Z.-Y., Liu, L., Xie, N., Lu, J., Liu, Z., Tang, Y., dkk., 2020. Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers. *Frontiers in Genetics*, **11**: 829.
- Hwang, I., Kim, J.E., Jeong, J.H., Ahn, J.-H., Jung, K.H., Son, B.H., dkk., 2023. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). *Breast Cancer Research and Treatment*, **201**: 193–204.
- Jones, M.E., Schoemaker, M.J., Wright, L.B., Ashworth, A., dan Swerdlow, A.J., 2017. Smoking and risk of breast cancer in the Generations Study cohort. *Breast cancer research: BCR*, **19**: 118.

- Kaklamani, V.G. dan Gradishar, W.J., 2003. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? *Clinical Breast Cancer*, **4 Suppl 1**: S26-33.
- Katano, A., Minamitani, M., Yamashita, H., dan Nakagawa, K., 2023. National Survey of Radiotherapy Utilization Trends from 2015 to 2019, Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. *JMA journal*, **6**: 342–345.
- Kelsey, J.L. (Editor), 1996. *Methods in Observational Epidemiology*, 2nd ed. ed, Monographs in epidemiology and biostatistics. Oxford University Press, New York.
- Kim, J. dan Hurria, A., 2013. Determining chemotherapy tolerance in older patients with cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **11**: 1494–1502.
- Ko, S.M., Lee, J., Bae, S.J., Baik, S.J., Ji, J., Kim, D., dkk., 2021. Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients. *British Journal of Cancer*, **125**: 119–125.
- Leso, V., Ercolano, M.L., Cioffi, D.L., dan Iavicoli, I., 2019. Occupational Chemical Exposure and Breast Cancer Risk According to Hormone Receptor Status: A Systematic Review. *Cancers*, **11**: 1882.
- Loibl, S., Weber, K.E., Timms, K.M., Elkin, E.P., Hahnen, E., Fasching, P.A., dkk., 2018. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. *Annals of Oncology*, **29**: 2341–2347.
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., dan Stanisławek, A., 2021a. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers*, **13**: 4287.
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., dan Stanisławek, A., 2021b. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers*, **13**: 4287.
- Lwanga, S.K. dan Lemeshow, S., 1991. *Sample Size Determination in Health Studies: A Practical Manual*. World Health Organization, Geneva.
- Magnoni, F., Alessandrini, S., Alberti, L., Polizzi, A., Rotili, A., Veronesi, P., dkk., 2021. Breast Cancer Surgery: New Issues. *Current Oncology (Toronto, Ont.)*, **28**: 4053–4066.
- Matyszewska, D., 2020. The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies. *Biochimica Et Biophysica Acta. Biomembranes*, **1862**: 183104.
- Mavroudis, D., Matikas, A., Malamos, N., Papakotoulas, P., Kakolyris, S., Boukovinas, I., dkk., 2016. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group

- (HORG). *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **27**: 1873–1878.
- McGuire, A., Brown, J.A.L., Malone, C., McLaughlin, R., dan Kerin, M.J., 2015. Effects of age on the detection and management of breast cancer. *Cancers*, **7**: 908–929.
- Milross, C.G., Mason, K.A., Hunter, N.R., Chung, W.K., Peters, L.J., dan Milas, L., 1996. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. *Journal of the National Cancer Institute*, **88**: 1308–1314.
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., dan Gianni, L., 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacological Reviews*, **56**: 185–229.
- Mizutani, H., Shiga, C., Imai, M., Ikemura, K., Kitamura, Y., Ohta, K., dkk., 2020. Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in the Presence of Copper (II). *Anticancer Research*, **40**: 5399–5404.
- Mo, C.-H., Ackbarkhan, Z., Gu, Y.-Y., Chen, G., Pang, Y.-Y., Dang, Y.-W., dkk., 2017. Invasive cribriform carcinoma of the breast: a clinicopathological analysis of 12 cases with review of literature. *International Journal of Clinical and Experimental Pathology*, **10**: 9917–9924.
- Morelli, M.B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., dkk., 2022. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. *Frontiers in Cardiovascular Medicine*, **9**: 847012.
- Mukrinin, W.U., Dr. apt. Arief Nurrochmad, M.S., dan Dr. apt. Fita Rahmawati, Sp.F., 2022. 'Dampak Penundaan Jadwal Kemoterapi Terhadap Rekurensi Dan Ketahanan Hidup Pada Pasien Kanker Payudara Di RSUP Dr.Sardjito Yogyakarta', . MAGISTER FARMASI KLINIK Universitas Gadjah Mada.
- Murwanti, R., Kholifah, E., Sudarmanto, B.S.A., dan Hermawan, A., 2020. 'Effect of curcumin on NF-κB P105/50 expression on triple-negative breast cancer (TNBC) and its possible mechanism of action', . Yogyakarta, Indonesia, hal. 040024.
- Nelson, H.D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O'Meara, E.S., dkk., 2012. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Annals of Internal Medicine*, **156**: 635–648.
- Nounou, M.I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., dan Syed-Sha-Qhattal, H., 2015. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast Cancer: Basic and Clinical Research*, **9s2**: BCBCR.S29420.
- Nugroho, A.E., Hermawan, A., Putri, D.D.P., Novika, A., dan Meiyanto, E., 2013. Combinational effects of hexane insoluble fraction of *Ficus septica* Burm. F. and doxorubicin chemotherapy on T47D breast cancer cells. *Asian Pacific Journal of Tropical Biomedicine*, **3**: 297–302.
- Nurmayeni, N. dan Windarti, I., 2022. Gambaran Subtipe Molekuler Kanker Payudara di Indonesia. *Jurnal Agromedicine*, **9**: 146–149.
- Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F.O., dan Ramírez-Valdespino, C.A., 2022. Subtypes of Breast Cancer,

- dalam: Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, FL, USA dan Mayrovitz, H.N. (Editor), *Breast Cancer*. Exon Publications, hal. 31–42.
- Osório, F., Barros, A.S., Peleteiro, B., Amendoeira, I., dan Fougo, J.L., 2023. Quality Indicators Compliance and Survival Outcomes in Breast Cancer according to Age in a Certified Center. *Cancers*, **15**: 1446.
- Panribowo, S., 2019. 'INFODATIN Beban Kanker di Indonesia', . *Riskesdas 2019*, .
- Paranita, I., 2019. Perubahan Dispersi Gelombang P dan Indeks Volume Atrium Kiri Pada Penderita Kanker Payudara yang Mendapat Kemoterapi Antrasiklin Sebagai Regimen Dasar.
- Patani, N., Martin, L., dan Dowsett, M., 2013. Biomarkers for the clinical management of breast cancer: International perspective. *International Journal of Cancer*, **133**: 1–13.
- Peters, G.J., van der Wilt, C.L., van Moorsel, C.J., Kroep, J.R., Bergman, A.M., dan Ackland, S.P., 2000. Basis for effective combination cancer chemotherapy with antimetabolites. *Pharmacology & Therapeutics*, **87**: 227–253.
- Plichta, J.K., Campbell, B.M., Mittendorf, E.A., dan Hwang, E.S., 2018. Anatomy and Breast Cancer Staging. *Surgical Oncology Clinics of North America*, **27**: 51–67.
- Polyzos, A., Malamos, N., Boukovinas, I., Adamou, A., Ziras, N., Kalbakis, K., dkk., 2010. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Research and Treatment*, **119**: 95–104.
- Prayoga, A.A., 2019. *Manajemen Kanker Payudara Komprehensif*. Airlangga University Press.
- Protani, M., Coory, M., dan Martin, J.H., 2010. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast Cancer Research and Treatment*, **123**: 627–635.
- Purwanto, I., 2020. Perbandingan Kesintasan Hidup Pasien Kanker Payudara Triple-negative yang Mendapatkan Kemoterapi Adjuvan Berbasis Antrasiklin dan Platinum: Kajian p53, TiLs, PD-L1, mTOR, miRNA-200c, miRNA-223, dan miRNA-21 terhadap Kesintasan Hidup Kanker Payudara Triple-negative sebagai Biomarker Prognostik.
- Rahal, S., Boher, J.M., Extra, J.M., Tarpin, C., Charafe-Jauffret, E., Lambaudie, E., dkk., 2015. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. *BMC cancer*, **15**: 697.
- Rainville, I., Hatcher, S., Rosenthal, E., Larson, K., Bernhisel, R., Meek, S., dkk., 2020. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2. *Breast Cancer Research and Treatment*, **180**: 503–509.

- Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., dan Suter, T., 2008. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **19**: 1530–1539.
- Regan, M.M., Pagani, O., Francis, P.A., Fleming, G.F., Walley, B.A., Kammler, R., dkk., 2015. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Research and Treatment*, **154**: 275–286.
- Reinisch, M., Huober, J., von Minckwitz, G., Blohmer, J.-U., Denkert, C., Hanusch, C., dkk., 2017. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy – A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. *The Breast*, **32**: 73–78.
- Rey-Vargas, L., Mejía-Henao, J.C., Sanabria-Salas, M.C., dan Serrano-Gomez, S.J., 2020. Effect of neoadjuvant therapy on breast cancer biomarker profile. *BMC cancer*, **20**: 675.
- Robert, J., 1994. Clinical pharmacokinetics of epirubicin. *Clinical Pharmacokinetics*, **26**: 428–438.
- Rose, B.S., Winer, E.P., dan Mamon, H.J., 2016. Perils of the Pathologic Complete Response. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **34**: 3959–3962.
- Roy, C., Choudhury, K.B., Pal, M., Saha, A., Bag, S., dan Banerjee, C., 2012. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer. *Indian Journal of Cancer*, **49**: 266–271.
- Rukminingsih, F., Andayani, T.M., Rahmawati, F., dan Widayati, K., 2017. Evaluasi Terapi Adjuvan dan Kejadian Relaps Pada Pasien Premenopausal Early Breast Cancer di RSUP DR. Sardjito Yogyakarta. *Jurnal Manajemen dan Pelayanan Farmasi*, **Vol 7**: .
- Ryu, R.J., Eyal, S., Kaplan, H.G., Akbarzadeh, A., Hays, K., Puhl, K., dkk., 2014. Pharmacokinetics of doxorubicin in pregnant women. *Cancer Chemotherapy and Pharmacology*, **73**: 789–797.
- Safitri, R. dan Andayani, T.M., 2015. 'Analisis Biaya Dan Faktor Yang Berpengaruh Terhadap Pengobatan Pasien Kemoterapi Kanker Payudara Jamkesmas Rawat Inap Di Rsup Dr Sardjito Yogyakarta', . S2 Magister Manajemen Farmasi Universitas Gadjah Mada.
- Sanker, Ms., Sistla, S., Manwar, Sa., dan Vivekanandam, S., 2016. Clinical and pathologic response following taxane based neoadjuvant chemotherapy in locally advanced breast cancer patients in a tertiary care centre in India. *Indian Journal of Cancer*, **53**: 220.
- Schneider, F., Pan, L., Ottenbruch, M., List, T., dan Gaich, T., 2021. The Chemistry of Nonclassical Taxane Diterpene. *Accounts of Chemical Research*, **54**: 2347–2360.

- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., dkk., 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **26 Suppl 5**: v8-30.
- Senolinggi, M.A., Mewengkang, M., dan Wantania, J., 2015. Hubungan Antara Usia Menarche Dengan Usia Menopause Pada Wanita Di Kecamatan Kakas Sulawesi Utara Tahun 2014. *e-CliniC*, **3**: .
- Shi, J., Gao, P., Song, Y., Chen, X., Li, Y., Zhang, C., dkk., 2017. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. *Scientific Reports*, **7**: 5319.
- Sikov, W.M., 2017. Which patients with early-stage triple-negative breast cancer should receive a platinum? *Clinical Advances in Hematology & Oncology: H&O*, **15**: 510–514.
- Stage, T.B., Bergmann, T.K., dan Kroetz, D.L., 2018. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. *Clinical Pharmacokinetics*, **57**: 7–19.
- Sun, L., Zhu, Y., Qian, Q., dan Tang, L., 2018. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. *Medicine*, **97**: e11220.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., dkk., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*, **71**: 209–249.
- Suresh, S., 2018. *Nursing Research And Statistics.*, 3rd ed. ELSEVIER INDIA.
- Tan, P.H., Ellis, I., Allison, K., Brogi, E., Fox, S.B., Lakhani, S., dkk., 2020. The 2019 World Health Organization classification of tumours of the breast. *Histopathology*, **77**: 181–185.
- Tan, Q.-W., Luo, T., Zheng, H., Tian, T.-L., He, P., Chen, J., dkk., 2017. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial. *Chinese Journal of Cancer*, **36**: 27.
- Tang, H., Liu, F., Li, H., Huang, X., dan Zhao, T., 2014. Pleomorphic carcinoma of breast: a case report and review of literature. *International Journal of Clinical and Experimental Pathology*, **7**: 5215–5220.
- Tang, N., Wang, Q., Wu, D., Zhang, S., Zhang, Y., dan Tao, L., 2013. Differential effects of paclitaxel and docetaxel on gap junctions affects their cytotoxicities in transfected HeLa cells. *Molecular Medicine Reports*, **8**: 638–644.
- Thabrany, H., Ramadani, R.V., Adawiyah, E., Sasongko, B.W., Pujisubekti, R., dan Jaya, C., 2021. *Fakta dan Data Capaian Program Jaminan Kesehatan Nasional 2015-2019*, 1st ed. DJSN BPJS.
- Thompson, D., 2002. Cancer Incidence in BRCA1 Mutation Carriers. *CancerSpectrum Knowledge Environment*, **94**: 1358–1365.
- Urien, S., Barré, J., Morin, C., Paccaly, A., Montay, G., dan Tillement, J.P., 1996. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. *Investigational New Drugs*, **14**: 147–151.

- Vasanth, J., Kannan, G., Goud, T., Palani, T., Vanitha, R., Anitha, R., dkk., 2011. Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. *Journal of young pharmacists: JYP*, **3**: 322–328.
- Venkatesh, P. dan Kasi, A., 2022. Anthracyclines, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Vuger, A.T., Tiscoski, K., Apolinario, T., dan Cardoso, F., 2022. Anthracyclines in the treatment of early breast cancer friend or foe? *The Breast*, **65**: 67–76.
- Weaver, B.A., 2014. How Taxol/paclitaxel kills cancer cells. *Molecular Biology of the Cell*, **25**: 2677–2681.
- Weigelt, B., Horlings, H., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L., dkk., 2008. Refinement of breast cancer classification by molecular characterization of histological special types. *The Journal of Pathology*, **216**: 141–150.
- Weiss, RaymondB., Sarosy, G., Clagett-Carr, K., Russo, M., dan Leyland-Jones, B., 1986. Anthracycline analogs The past, present, and future. *Cancer Chemotherapy and Pharmacology*, **18**: .
- Winarni, W. dan Dyaswati, R., 2020. Memasuki Masa Usia Menopause Ditinjau Dari Usia Menarche Dan Jumlah Anak. *Jurnal Kebidanan Indonesia*, **11**: 82.
- Yang, Y., Chen, D., Zhong, D., dan Yi, Z., 2023. Association of body mass index with survival in U.S. cancer survivors: a cross-sectional study of NHANES 1999-2018. *Frontiers in Oncology*, **13**: 1180442.